ArticleFrontiers in immunology2026
TRIM21 suppresses uterine corpus endometrial carcinoma progression by promoting K48 -linked ubiquitination and degradation of SOAT1.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine corpus endometrial carcinoma (UCEC) is one of the most common gynecological malignancies, and its progression is closely associated with dysregulated protein homeostasis and metabolic reprogramming. TRIM21 is an E3 ubiquitin ligase implicated in tumor regulation, but its role in UCEC remains unclear. Methods: Datasets from TCGA, CPTAC, and GEO were used to assess the expression pattern, clinical significance, and cellular distribution of TRIM21 in UCEC. TRIM21 expression was validated by immunohistochemistry, qRT-PCR, western blotting, and immunofluorescence. Gain-of-function assays, including CCK-8, colony formation, Transwell migration, apoptosis assays, lipid droplet staining, and xenograft experiments, were performed to determine the biological effects of TRIM21. Quantitative proteomics, immunoprecipitation coupled with mass spectrometry, co-immunoprecipitation, cycloheximide chase, ubiquitination assays, and rescue experiments were conducted to investigate the underlying mechanism. Results: TRIM21 was significantly downregulated in UCEC tissues and cell lines and was associated with favorable prognosis and less aggressive clinicopathological features. TRIM21 overexpression inhibited proliferation, migration, lipid droplet accumulation, and tumor growth, while promoting apoptosis. Mechanistically, SOAT1 was identified as a novel interacting protein of TRIM21. TRIM21 negatively regulated SOAT1 by promoting its K48-linked ubiquitination and proteasomal degradation, thereby reducing SOAT1 protein stability. Restoration of SOAT1 partially reversed the inhibitory effects of TRIM21 on malignant phenotypes and its pro-apoptotic effects. Conclusion: TRIM21 functions as a tumor suppressor in UCEC by promoting K48-linked ubiquitination and degradation of SOAT1. These findings reveal a novel mechanism linking protein homeostasis to lipid metabolic regulation in UCEC and suggest that TRIM21 and SOAT1 may serve as potential biomarkers and therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.